Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells

NCT05088356 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05088356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05088356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 7, 2021
Completion date
May 31, 2028
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, advanced hematologic malignancies, allogeneic hematopoietic cell transplantation (hct), chronic myelogenous leukemia, myelodysplastic syndromes, myeloproliferative disorders